Xin Lang Cai Jing·2025-08-06 07:49Core Viewpoint - Junshi Biosciences is positioned as a leading innovative pharmaceutical company in China, focusing on the development and commercialization of first-in-class and best-in-class drugs, with a comprehensive industry chain from drug discovery to large-scale production and global clinical research [2][3]. Company Overview - Junshi Biosciences was established on December 27, 2012, and went public on July 15, 2020. The company is headquartered in Shanghai and specializes in the research and commercialization of monoclonal antibody drugs and other therapeutic protein drugs [7]. - The main revenue sources for the company include drug sales (84.18%), technology licensing and royalties (12.08%), and other income (3.73%) [7]. Recent Developments - On October 27, 2023, Junshi Biosciences announced a collaboration with Peking University, the Institute of Microbiology of the Chinese Academy of Sciences, Shanxi Advanced Innovation Research Institute, and Beihang University to jointly develop a monkeypox recombinant protein vaccine [3]. - The company’s subsidiary, JunTuo Biotech, is involved in the development of vaccine-related products, including monkeypox and Zika vaccines, which are currently in the preclinical development stage [3]. Financial Performance - For the period from January to March 2025, Junshi Biosciences reported a revenue of 5.01 billion yuan, representing a year-on-year growth of 31.46%. However, the net profit attributable to the parent company was -2.35 billion yuan, showing a year-on-year increase of 17.01% [8]. Market Activity - On August 6, 2023, Junshi Biosciences' stock rose by 4.61%, with a trading volume of 1.663 billion yuan and a turnover rate of 5.09%, bringing the total market capitalization to 42.382 billion yuan [1].